Melissa Hamrick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Melissa Hamrick has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Aaron J. Schmitz
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, USA
1 shared publication - Adriane L. Baylis
Nationwide Children's Hospital
1 shared publication - Alaullah Sheikh
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine
1 shared publication - Ali H. Ellebedy
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, USA
1 shared publication - Alyssa Fogolin
Eastern Virginia Medical School MPA Program
1 shared publication - Andrew B. Ward
Scripps Research Institute
1 shared publication
Latest Publications
- 6 November 2026
- Published by SAGE Publications in The Cleft Palate Craniofacial Journal
The Horizontal Split Technique for Posterior Pharyngeal Flap Surgery: Speech and Airway Outcomes in 220 Patients
Objective: The purpose of this 10-year retrospective review was to report our single-center outcomes using the posterior pharyngeal flap (PPF) horizontal split technique to treat patients with syndromic and non-syndromic velopharyngeal dysfunction (VPD). Design: Retrospective review (2011-2021). Setting: A tertiary pediatric institution. Patients: Patients with VPD (4-21 years old). Interventions: PPF surgery using the horizontal split inset technique by 2 surgeons. Main Outcome Measures: Evaluated factors included demographics, VPD characteristics, and pre-operative speech evaluation. Evaluated outcomes included complications, revisional VPD surgery rates, post-operative resonance, nasometry scores, and the apnea-hypopnea index (AHI). Results: Two hundred and twenty children (median age: 6.9 years) underwent surgery. The median operative time was 47 min. Most patients (95%) achieved improved resonance, with 89% achieving mild or no hypernasality. Median nasalance scores significantly decreased (pre-operative: 42, post-operative: 18). Of 137 patients who underwent a post-operative polysomnogram, 18 patients had an AHI ≥5; 2 patients with syndromic diagnoses underwent PPF takedown. Ten patients underwent revisional VPD surgery. Patients with 22qDS (22q11.2 deletion syndrome) or non-cleft VPD had an increased risk of demonstrating significant residual hypernasality requiring revisional surgery. Conclusions: This simple, reproducible PPF surgical technique yields reliably improved resonance in patients with syndromic and non-syndromic VPD. Patients with 22qDS and those with non-cleft VPD may have higher odds of demonstrating residual hypernasality and needing additional surgery. Although there is low risk of flap takedown for obstructive sleep apnea (OSA), long-term airway monitoring remains essential.
- 6 November 2026
- Published by SAGE Publications in The Cleft Palate Craniofacial Journal
The Horizontal Split Technique for Posterior Pharyngeal Flap Surgery: Speech and Airway Outcomes in 220 Patients
Objective: The purpose of this 10-year retrospective review was to report our single-center outcomes using the posterior pharyngeal flap (PPF) horizontal split technique to treat patients with syndromic and non-syndromic velopharyngeal dysfunction (VPD). Design: Retrospective review (2011-2021). Setting: A tertiary pediatric institution. Patients: Patients with VPD (4-21 years old). Interventions: PPF surgery using the horizontal split inset technique by 2 surgeons. Main Outcome Measures: Evaluated factors included demographics, VPD characteristics, and pre-operative speech evaluation. Evaluated outcomes included complications, revisional VPD surgery rates, post-operative resonance, nasometry scores, and the apnea-hypopnea index (AHI). Results: Two hundred and twenty children (median age: 6.9 years) underwent surgery. The median operative time was 47 min. Most patients (95%) achieved improved resonance, with 89% achieving mild or no hypernasality. Median nasalance scores significantly decreased (pre-operative: 42, post-operative: 18). Of 137 patients who underwent a post-operative polysomnogram, 18 patients had an AHI ≥5; 2 patients with syndromic diagnoses underwent PPF takedown. Ten patients underwent revisional VPD surgery. Patients with 22qDS (22q11.2 deletion syndrome) or non-cleft VPD had an increased risk of demonstrating significant residual hypernasality requiring revisional surgery. Conclusions: This simple, reproducible PPF surgical technique yields reliably improved resonance in patients with syndromic and non-syndromic VPD. Patients with 22qDS and those with non-cleft VPD may have higher odds of demonstrating residual hypernasality and needing additional surgery. Although there is low risk of flap takedown for obstructive sleep apnea (OSA), long-term airway monitoring remains essential.
- Open Access
Repeat modules and N-linked glycans define structure and antigenicity of a critical enterotoxigenic E. coli adhesin
Enterotoxigenic Escherichia coli (ETEC) cause hundreds of millions of cases of infectious diarrhea annually, predominantly in children from low-middle income regions. Notably, in children, as well as human volunteers challenged with ETEC, diarrheal severity is significantly increased severity in blood group A (bgA) individuals. EtpA, is a secreted glycoprotein adhesin that functions as a blood group A lectin to promote critical interactions between ETEC and blood group A glycans on intestinal epithelia for effective bacterial adhesion and toxin delivery. EtpA is highly immunogenic resulting in robust antibody responses following natural infection and experimental challenge of human volunteers with ETEC. To understand how EtpA directs ETEC-blood group A interactions and stimulates adaptive immunity, we mutated EtpA, mapped its glycosylation by mass-spectrometry (MS), isolated polyclonal (pAbs) and monoclonal antibodies (mAbs) from vaccinated mice and ETEC-infected human volunteers, and determined structures of antibody-EtpA complexes by cryo-electron microscopy. Both bgA and mAbs that inhibited EtpA-bgA interactions and ETEC adhesion, bound to the C-terminal repeat domain highlighting this region as crucial for ETEC pathogen-host interaction. MS analysis uncovered extensive and heterogeneous N-linked glycosylation of EtpA and cryo-EM structures revealed that mAbs directly engage these unique glycan containing epitopes. Finally, electron microscopy-based polyclonal epitope mapping revealed antibodies targeting numerous distinct epitopes on N and C-terminal domains, suggesting that EtpA vaccination generates responses against neutralizing and decoy regions of the molecule. Collectively, we anticipate that these data will inform our general understanding of pathogen-host glycan interactions and adaptive immunity relevant to rational vaccine subunit design. Author summary: Enterotoxigenic E. coli (ETEC), a leading cause of diarrhea disproportionately affecting young children in low-income regions, are a priority for vaccine development. Individuals possessing A blood-type are more susceptible to severe cholera-like disease. EtpA, a secreted, immunogenic, blood group A binding protein, is a current vaccine target antigen. Here, we determined the atomic structure of EtpA in complex with protective as well as non-protective monoclonal antibodies targeting two different domains of the protein, allowing us to pinpoint key regions involved in blood-group A antigen recognition and uncover the mechanism of antibody-based protection. In addition, we show through mass-spectrometry that EtpA is extensively and heterogeneously glycosylated at surface-exposed asparagine residues by a promiscuous and low-fidelity glycosyltransferase, EtpC, and that this unique form of bacterial glycosylation is critical for to development of protective immune responses. Lastly, polyclonal antibodies from vaccinated mice as well as monoclonal antibodies obtained from ETEC-infected human volunteers revealed that the highly antigenic surface of EtpA exhibits both protective and non-protective epitopes. These results greatly expand our understanding of ETEC pathogenesis, and the immune responses elicited by these common infections, providing valuable information to aid in the rational design and testing of subunit vaccines.
Open AccessRepeat modules and N-linked glycans define structure and antigenicity of a critical enterotoxigenic E. coli adhesin
Enterotoxigenic Escherichia coli (ETEC) cause hundreds of millions of cases of infectious diarrhea annually, predominantly in children from low-middle income regions. Notably, in children, as well as human volunteers challenged with ETEC, diarrheal severity is significantly increased severity in blood group A (bgA) individuals. EtpA, is a secreted glycoprotein adhesin that functions as a blood group A lectin to promote critical interactions between ETEC and blood group A glycans on intestinal epithelia for effective bacterial adhesion and toxin delivery. EtpA is highly immunogenic resulting in robust antibody responses following natural infection and experimental challenge of human volunteers with ETEC. To understand how EtpA directs ETEC-blood group A interactions and stimulates adaptive immunity, we mutated EtpA, mapped its glycosylation by mass-spectrometry (MS), isolated polyclonal (pAbs) and monoclonal antibodies (mAbs) from vaccinated mice and ETEC-infected human volunteers, and determined structures of antibody-EtpA complexes by cryo-electron microscopy. Both bgA and mAbs that inhibited EtpA-bgA interactions and ETEC adhesion, bound to the C-terminal repeat domain highlighting this region as crucial for ETEC pathogen-host interaction. MS analysis uncovered extensive and heterogeneous N-linked glycosylation of EtpA and cryo-EM structures revealed that mAbs directly engage these unique glycan containing epitopes. Finally, electron microscopy-based polyclonal epitope mapping revealed antibodies targeting numerous distinct epitopes on N and C-terminal domains, suggesting that EtpA vaccination generates responses against neutralizing and decoy regions of the molecule. Collectively, we anticipate that these data will inform our general understanding of pathogen-host glycan interactions and adaptive immunity relevant to rational vaccine subunit design. Author summary: Enterotoxigenic E. coli (ETEC), a leading cause of diarrhea disproportionately affecting young children in low-income regions, are a priority for vaccine development. Individuals possessing A blood-type are more susceptible to severe cholera-like disease. EtpA, a secreted, immunogenic, blood group A binding protein, is a current vaccine target antigen. Here, we determined the atomic structure of EtpA in complex with protective as well as non-protective monoclonal antibodies targeting two different domains of the protein, allowing us to pinpoint key regions involved in blood-group A antigen recognition and uncover the mechanism of antibody-based protection. In addition, we show through mass-spectrometry that EtpA is extensively and heterogeneously glycosylated at surface-exposed asparagine residues by a promiscuous and low-fidelity glycosyltransferase, EtpC, and that this unique form of bacterial glycosylation is critical for to development of protective immune responses. Lastly, polyclonal antibodies from vaccinated mice as well as monoclonal antibodies obtained from ETEC-infected human volunteers revealed that the highly antigenic surface of EtpA exhibits both protective and non-protective epitopes. These results greatly expand our understanding of ETEC pathogenesis, and the immune responses elicited by these common infections, providing valuable information to aid in the rational design and testing of subunit vaccines.
- 9 January 2023
- Published by Wiley in Wound Repair and Regeneration
- Vol. 31 (2) , 193-198
Iliac vein recanalisation and stenting accelerate healing of venous leg ulcers associated with severe venous outflow obstruction
Obstruction involving the iliac veins and/or inferior vena cava is highly comorbid in patients with chronic venous leg ulcers and is a barrier to healing. Intervention with venous stenting is recommended to promote wound healing; however, there is limited data to quantify the effects of venous outflow restoration on wound healing. We retrospectively identified patients with venous ulcers and comorbid venous outflow obstruction. Data regarding demographics, wound size, degree of obstruction, interventions, wound healing and recurrence were collected. Intervention was performed when possible and patients were grouped based on whether or not the venous outflow was reopened successfully and maintained for at least 1 year. Outcomes, including time to wound healing, wound recurrence, stent patency and ulcer-free time, were measured. Patients who maintained a patent venous outflow tract experienced higher rates of wound healing (79.3%) compared to those with persistent outflow obstruction (22.6%) at 12 months (p < 0.001). Ulcer-free time for the first year was also greater with patent venous outflow (7.6 +/- 4.4 months versus 1.8 +/- 3.0 months, p < 0.0025). Patients with severe obstruction of the venous outflow tract experience poor healing of VLUs despite appropriate wound care. Healing time is improved and ulcer-free time increased after venous intervention with stenting to eliminate obstruction.
- 9 January 2023
- Published by Wiley in Wound Repair and Regeneration
- Vol. 31 (2) , 193-198
Iliac vein recanalisation and stenting accelerate healing of venous leg ulcers associated with severe venous outflow obstruction
Obstruction involving the iliac veins and/or inferior vena cava is highly comorbid in patients with chronic venous leg ulcers and is a barrier to healing. Intervention with venous stenting is recommended to promote wound healing; however, there is limited data to quantify the effects of venous outflow restoration on wound healing. We retrospectively identified patients with venous ulcers and comorbid venous outflow obstruction. Data regarding demographics, wound size, degree of obstruction, interventions, wound healing and recurrence were collected. Intervention was performed when possible and patients were grouped based on whether or not the venous outflow was reopened successfully and maintained for at least 1 year. Outcomes, including time to wound healing, wound recurrence, stent patency and ulcer-free time, were measured. Patients who maintained a patent venous outflow tract experienced higher rates of wound healing (79.3%) compared to those with persistent outflow obstruction (22.6%) at 12 months (p < 0.001). Ulcer-free time for the first year was also greater with patent venous outflow (7.6 +/- 4.4 months versus 1.8 +/- 3.0 months, p < 0.0025). Patients with severe obstruction of the venous outflow tract experience poor healing of VLUs despite appropriate wound care. Healing time is improved and ulcer-free time increased after venous intervention with stenting to eliminate obstruction.